Last week was the launch of the latest issue of Index on Censorship’s award winning magazine. A particularly topical one for us at SAGE this time, as it focusses on Science. Natasha at Index kindly let us repost her summary of the event which took place last tuesday below. You can read it in full here, and you can catch a video of the whole event here.
“The philosopher Baroness O’Neill opened the discussion by pointing out that the Protection of Freedoms Bill places greater pressure on academics, calling as it does for openness. But this is not a new concept for scientists — the Royal Society is based on openness, viewing science as a public enterprise. What was difficult, she said, at a time when transparency is so valued by so many, is how open data might be “reusable” in a way that is useful and productive.
Sir Mark Walport, director of the Wellcome Trust, agreed. “Science”, he said, “has led the way with openness”. But he warned against the dangers of raw data, which he likened to raw sewage (easily themost tweeted comment of the night, and repeated throughout the event’s discussion). Like O’Neill, Walport called for “useful” data sets to be available to the public so that serious misinterpretation of this unsorted data did not stand in the way of public knowledge.
But the journalist and campaigner George Monbiot called for full access to data, saying that it was counterproductive to allow scientists to determine who accesses information. He spoke of the public’s suspicion about science; at times communication between the scientific community and the public was simply a “tragedy of human incomprehension”. The public are told they need to know more and more about science and yet there are significant barriers to making this possible. He admitted the media were partly to blame, but stated that openness would help ease the public’s suspicion. As Fred Pearce writes in the magazine, “the fuss over climategate showed that the world is increasly unwilling to accept the message that ‘we are scientists; trust us’.”
Professor David Colquhoun called for greater openness in clinical trials. The competitive nature of the scientific community is exploited, he lamented, particularly within the drugs industry. As a result, important research is kept from the public, often because while clinical tests must be registered, the results do not have to be published. It’s a subject explored in detail by Deborah Cohen, BMJ investigations editor, in the current issue of the magazine too. Colquhoun offered that competition also meant that a huge amount of research was being carried out and not all of it to a good standard. Perhaps, he said, a reduction in the number of studies would bring about higher quality research.”